Metagenomi net loss widens 38.05% to $27.48 million in Q2 FY26

Reuters2026/08/10 20:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Metagenomi Therapeutics posted a net loss of USD 27.48 million, or USD 0.73 per share, for Q2 2026.
Collaboration revenue turned negative to a loss of USD 257,000, from revenue in the year-earlier quarter.
Operating loss widened to USD 28.77 million as operating expenses eased to USD 28.52 million, helped by lower G&A spending.
Cash, cash equivalents, and available-for-sale marketable securities fell to USD 120.7 million at June 30, with runway projected through Q4 2027.
MGX-001 hemophilia A IND-enabling work is expected to finish by end-Q3 2026; IND filing targeted for Q4 2026 with trials planned in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metagenomi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101605PRIMZONEFULLFEED9806967) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Metagenomi net loss widens 38.05% to $27.48 million in Q2 FY26

You may also like

Crypto prices